NAV

Propyphenazone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Propyphenazone
DrugBank Accession Number
DB13524
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 230.311
Monoisotopic: 230.141913208
Chemical Formula
C14H18N2O
Synonyms
  • 1-Phenyl-2,3-dimethyl-4-isopropyl-3-pyrazolin-5-one
  • 1-Phenyl-2,3-dimethyl-4-isopropylpyrazol-5-one
  • 4-Isopropyl-1,5-dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one
  • 4-Isopropylantipyrine
  • Isopropylantipyrine
  • Isopropylphenazone
  • Propifenazona
  • Propyphenazone
  • Propyphenazonum

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbacavirPropyphenazone may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Abciximab.
AcebutololPropyphenazone may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Propyphenazone.
AcemetacinThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Acenocoumarol.
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Propyphenazone.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Propyphenazone.
AclidiniumPropyphenazone may decrease the excretion rate of Aclidinium which could result in a higher serum level.
AcrivastinePropyphenazone may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Yoshipyrin
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Adolomed 250 mg/300 mg/50 mg TablettenPropyphenazone (250 mg) + Acetaminophen (300 mg) + Caffeine (50 mg)TabletOralKwizda Pharma Gmb H1986-08-22Not applicableAustria flag
ALJIL 150 MG/300 MG/50 MG TABLET, 20 ADETPropyphenazone (150 mg) + Acetaminophen (300 mg) + Caffeine (50 mg)TabletOralRECORDATİ İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
BIOPTAN DRAJE, 30 ADETPropyphenazone (250 mg) + Caffeine (50 mg)Tablet, coatedOralBİOFARMA İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
DERMAN 300/100/50 MG KAŞE, 1 KAŞEPropyphenazone (100 mg) + Acetaminophen (300 mg) + Caffeine (50 mg)PowderOralDERMAN İLAÇ SAN.VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
GeworinPropyphenazone (150 mg/1) + Acetaminophen (300 mg/1) + Caffeine (50 mg/1)TabletOralOASIS TRADING2018-11-20Not applicableUS flag
GeworinPropyphenazone (150 mg/1) + Acetaminophen (300 mg/1)TabletOralLydia Co., Ltd.2023-02-11Not applicableUS flag
MİNAMOL PLUS 250MG/150MG/50MG TABLET, 20 ADETPropyphenazone (150 mg) + Acetaminophen (250 mg) + Caffeine (50 mg)TabletOralPHARMACTİVE İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
MİNAMOL PLUS 250MG/150MG/50MG TABLET, 30 ADETPropyphenazone (150 mg) + Acetaminophen (250 mg) + Caffeine (50 mg)TabletOralPHARMACTİVE İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
MINOSET PLUS 250 MG/150 MG/50 MG TABLET, 20 ADETPropyphenazone (150 mg) + Acetaminophen (250 mg) + Caffeine (50 mg)TabletOralBAYER TÜRK KİMYA SAN. LTD. ŞTİ.2020-08-14Not applicableTurkey flag
MINOSET PLUS 250 MG/150 MG/50 MG TABLET, 30 ADETPropyphenazone (150 mg) + Acetaminophen (250 mg) + Caffeine (50 mg)TabletOralBAYER TÜRK KİMYA SAN. LTD. ŞTİ.2020-08-14Not applicableTurkey flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
GeworinPropyphenazone (150 mg/1) + Acetaminophen (300 mg/1)TabletOralLydia Co., Ltd.2023-02-11Not applicableUS flag
PANALGINE TABLET, 30 ADETPropyphenazone (150 mg) + Acetaminophen (300 mg) + Caffeine (30 mg)TabletOralATABAY İLAÇ FABRİKASI A.Ş.2020-08-14Not applicableTurkey flag
PAROL PLUS TABLET, 30 ADETPropyphenazone (150 mg) + Acetaminophen (250 mg) + Caffeine (50 mg)TabletOralATABAY KİMYA SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

ATC Codes
N02BB74 — Propyphenazone, combinations with psycholepticsN02BB54 — Propyphenazone, combinations excl. psycholepticsN02BB04 — Propyphenazone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Pyrazoles
Direct Parent
Phenylpyrazoles
Alternative Parents
Pyrazolones / Benzene and substituted derivatives / Vinylogous amides / Heteroaromatic compounds / Lactams / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides
show 1 more
Substituents
Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Lactam / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxide / Organic oxygen compound
show 6 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyrazolone (CHEBI:135538)
Affected organisms
Not Available

Chemical Identifiers

UNII
OED8FV75PY
CAS number
479-92-5
InChI Key
PXWLVJLKJGVOKE-UHFFFAOYSA-N
InChI
InChI=1S/C14H18N2O/c1-10(2)13-11(3)15(4)16(14(13)17)12-8-6-5-7-9-12/h5-10H,1-4H3
IUPAC Name
1,5-dimethyl-2-phenyl-4-(propan-2-yl)-2,3-dihydro-1H-pyrazol-3-one
SMILES
CC(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1

References

General References
  1. TITCK Product Information: Minamol Plus (acetaminophen/caffeine/propyphenazone) oral tablets [Link]
KEGG Drug
D01380
ChemSpider
3646
RxNav
34710
ChEBI
135538
ChEMBL
CHEMBL28318
ZINC
ZINC000000049151
Wikipedia
Propyphenazone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMenstrual Distress (Dysmenorrhea)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule
PowderOral
TabletOral
SuppositoryRectal
Tablet, coatedOral
Tablet, film coatedOral
Suppository
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility9.26 mg/mLALOGPS
logP1.94ALOGPS
logP2.35Chemaxon
logS-1.4ALOGPS
pKa (Strongest Basic)0.47Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area23.55 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity69.92 m3·mol-1Chemaxon
Polarizability26.43 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0590000000-b45ad15ef4971f839e87
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0fsa-2920000000-5448545b1fe746778dc3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001r-0690000000-a62e5f9e1a528954b203
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0910000000-3af6eb80085a93ebcbb4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0190000000-d499d58b0fccdbd7758d

Drug created at June 23, 2017 20:43 / Updated at September 28, 2021 21:54